Renji Hospital
上海交通大学医学院附属仁济医院
Listed for 28 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
No official website checked for this hospital yet.
Research at Renji Hospital
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Nasopharyngeal carcinoma鼻咽癌2 papers led2 open trials led
- Oesophageal squamous cell carcinoma食管鳞状细胞癌8 papers led1 open trial led
- Hepatocellular carcinoma肝细胞癌104 papers led5 open trials led
- Stomach cancer胃癌65 papers led5 open trials led
- Hepatoblastoma肝母细胞瘤3 papers led
- Retinoblastoma视网膜母细胞瘤1 paper led
- Chordoma脊索瘤1 paper led
- Osteosarcoma骨肉瘤3 papers led
- Gastrointestinal stromal tumour胃肠道间质瘤10 papers led
- Neuroblastoma神经母细胞瘤2 papers led
- Multiple myeloma多发性骨髓瘤24 papers led2 open trials led
- Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症3 papers led
- Atypical haemolytic uraemic syndrome非典型溶血性尿毒症综合征1 paper led
- Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病11 papers led1 open trial led
- IgG4-related diseaseIgG4相关性疾病2 papers led
- Myasthenia gravis重症肌无力3 papers led1 open trial led
- Biliary atresia胆道闭锁3 papers led
- Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎2 papers led
- Takayasu arteritis大动脉炎0 papers led
- Idiopathic pulmonary fibrosis特发性肺纤维化0 papers led
- Amyotrophic lateral sclerosis肌萎缩侧索硬化症3 papers led
- Fabry disease法布雷病1 paper led
- Duchenne muscular dystrophy杜氏肌营养不良0 papers led
- Behçet disease白塞病2 papers led
- IgA nephropathyIgA 肾病6 papers led
- Primary biliary cholangitis原发性胆汁性胆管炎17 papers led1 open trial led
- Primary sclerosing cholangitis原发性硬化性胆管炎5 papers led
- Hereditary angioedema遗传性血管性水肿2 papers led
Not listed for: Ewing sarcoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Beta thalassaemia, Haemophilia A, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Moyamoya disease, Wilson disease, Hepatic echinococcosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Pompe disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Nasopharyngeal carcinoma
鼻咽癌Led 2 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.08%.
- Open trials as a site
- 0
- led by another institution
10 hospitals in Shanghai for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingTrop2-targeted immunoPET Imaging of Solid Tumors
- Phase
- Phase 2/Phase 3
- Started
- 2024-12
- Registry
- NCT06851663
Age 18 years to 75 years (registered criteria)
Led by Renji HospitalShanghai
- RecruitingCD70-targeted immunoPET Imaging of Malignant Cancers
- Phase
- Phase 2
- Started
- 2024-12
- Registry
- NCT06852638
Age 18 years to 80 years (registered criteria)
Led by Renji HospitalShanghai
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led2
All its trials on ClinicalTrials.gov, any status2
More papers found outside PubMed (not counted)4
- DTL promotes glycolysis and tumor progression in nasopharyngeal carcinoma cells by degrading KAT2B and activating the PI3K/AKT/mTOR pathway
- Additional file 4 of RNF38 suppress growth and metastasis via ubiquitination of ACTN4 in nasopharyngeal carcinoma
- Additional file 6 of RNF38 suppress growth and metastasis via ubiquitination of ACTN4 in nasopharyngeal carcinoma
- Nimotuzumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma (NPC): A prospective, randomized-controlled, double-blinded, multicenter phase III clinical trial.
Cancer
Oesophageal squamous cell carcinoma
食管鳞状细胞癌Led 8 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.3%.
18 hospitals in Shanghai for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- Not yet recruitingRetlirafusp Alfa Combined With Chemoradiotherapy in Unresectable ESCC
- Phase
- N/A
- Started
- 2026-09
- Registry
- NCT07769866
Age 18 years to 75 years (registered criteria)
Led by Renji HospitalShanghai
- RecruitingA Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Phase
- Phase 1
- Started
- 2024-07
- Registry
- NCT06465069
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Shanghai
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led8
- Amphiregulin and Epiregulin Confer Radioresistance in Esophageal Squamous Cell Carcinoma Through Oxidative Phosphorylation.
- Neoadjuvant chemoradiotherapy combined with sequential perioperative toripalimab in locally advanced esophageal squamous cell cancer.
- FOXP3 expression in esophageal squamous cell carcinoma : Implications for cetuximab sensitivity and therapeutic strategies.
- Analysis of the Amine Submetabolome Using Novel Isotope-Coded Pyrylium Salt Derivatization and LC-MS: Herbs and Cancer Tissues as Cases.
- The predictive value of peripheral blood cells and lymphocyte subsets in oesophageal squamous cell cancer patients with neoadjuvant chemoradiotherapy.
- Identifying key mutations of radioresponsive genes in esophageal squamous cell carcinoma.
- Circular RNA hsa_circ_0003823 promotes the Tumor Progression, Metastasis and Apatinib Resistance of Esophageal Squamous Cell Carcinoma by miR-607/CRISP3 Axis.
- Diffusion-weighted MRI and 18F-FDG PET/CT in assessing the response to neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.
All its trials on ClinicalTrials.gov, any status6
- Retlirafusp Alfa Combined With Chemoradiotherapy in Unresectable ESCC
- NCRT Combined With Sequential Perioperative PD-1 Inhibitor for LAESCC
- Neoadjuvant Chemoradiotherapy Combined With Perioperative Toripalimab in Locally Advanced Esophageal Cancer
- Multimodal Functional Imaging Combined With Metabolomics in Predicting the Efficacy of nCRT for Locally Advanced ESCC
- A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma
More papers found outside PubMed (not counted)6
- The feasibility and tolerability of anlotinib plus PD-1 blockades among patients with previously immunotherapy treated advanced esophageal squamous cell carcinoma (ESCC): Update results of a retrospective exploratory study.
- P-162 Preliminary results of the feasibility and tolerability of anlotinib plus PD-1 blockades among patients with previously immunotherapy treated advanced esophageal squamous cell carcinoma (ESCC): A retrospective exploratory study
- 70P A retrospective real-world study of anlotinib plus PD-1 inhibitors in advanced esophageal squamous cell carcinoma (ESCC) previously treated with immune checkpoint inhibitors (ICIs)
- APEC: Efficacy and toxicity of anlotinib plus PD-1 inhibitors as later-line therapy in advanced/metastatic esophageal squamous cell carcinoma (ESCC): A retrospective real-world study.
- Nimotuzumab plus concurrent chemo-radiotherapy versus chemo-radiotherapy in unresectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim analysis from a prospective, randomized-controlled, double-blinded, multicenter, an
- First-line pembrolizumab plus chemotherapy versus chemotherapy in patients with advanced esophageal cancer: Chinese subgroup analysis of KEYNOTE-590.
Cancer
Hepatocellular carcinoma
肝细胞癌Led 104 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.7%.
15 hospitals in Shanghai for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma
Open trials with this hospital 6
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingFGF19 Overexpression Combination Unified Study in HCC-19
- Phase
- Phase 2
- Started
- 2025-04
- Registry
- NCT06978933
Age 18 years to Not stated (registered criteria)
Led by Renji HospitalShanghai
- RecruitingDEB-TACE Prior to Liver Transplantation in the Treatment of HCC
- Phase
- Phase 4
- Started
- 2024-10
- Registry
- NCT06353126
Age 18 years to 75 years (registered criteria)
Led by Renji HospitalShanghai
- RecruitingProspective Real-World Study of HAIC With Raltitrexed or 5-Fluorouracil for the Treatment of Hepatocellular Carcinoma
- Phase
- N/A
- Started
- 2024-08
- Registry
- NCT06519578
Age 18 years to 75 years (registered criteria)
Led by Renji HospitalShanghai
- RecruitingGPC3-directed CAR-T in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma
- Phase
- N/A
- Started
- 2023-01
- Registry
- NCT05926726
Age 18 years to 75 years (registered criteria)
Led by Renji HospitalShanghai
- Not yet recruitingHAIC + Atezolizumab Plus Bevacizumab in Unresectable HCC
- Phase
- Not given
- Started
- 2025-08
- Registry
- NCT07045558
Age 18 years to 75 years (registered criteria)
Led by Renji HospitalShanghai
- RecruitingABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
- Phase
- Phase 2
- Started
- 2025-06
- Registry
- NCT07327034
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Tianjin, Wuhan, Xi'an, Xuzhou, Yinchuan, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led104
- Oridonin induces ferroptosis by inhibiting ubiquitin-mediated degradation of HMOX1 in hepatocellular carcinoma.
- A therapeutic strategy integrating ultrasound-guided microwave ablation with nanocomposite hydrogels to enhance autophagy and suppress tumor growth in hepatocellular carcinoma.
- Cardiorespiratory fitness-associated gene signature for prognosis in hepatocellular Carcinoma: Computational prediction and in vivo validation.
- Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer.
- Novel molecular mechanisms of immune evasion in hepatocellular carcinoma: NSUN2-mediated increase of SOAT2 RNA methylation.
- Therapeutic Potential of STE20-Type Kinase STK25 Inhibition for the Prevention and Treatment of Metabolically Induced Hepatocellular Carcinoma.
- Lenvatinib-activated NDUFA4L2/IL33/PADI4 pathway induces neutrophil extracellular traps that inhibit cuproptosis in hepatocellular carcinoma.
- PTEN loss and ERBB2/ERBB3-mediated AKT reactivation drive resistance to MET inhibition in MET-amplified hepatocellular carcinoma.
- Role of immune cell homeostasis in research and treatment response in hepatocellular carcinoma.
- Criteria and prognostic models for patients with hepatocellular carcinoma undergoing liver transplantation.
- DYRK1A-TGF-β signaling axis determines sensitivity to OXPHOS inhibition in hepatocellular carcinoma.
- PRMT1-mediated modification of H4R3me2a promotes liver cancer progression by enhancing the transcriptional activity of SOX18.
- Rescued with T and B lymphocytes depletion therapy for immune checkpoint inhibitor-associated transplant rejection.
- Atezolizumab and Bevacizumab prior to liver transplantation in hepatic angiosarcoma mimicking hepatocellular carcinoma.
- SNX17 mediates STAT3 activation to promote hepatocellular carcinoma progression via a retromer dependent mechanism.
- Inhibition of liver cancer cell growth by metabolites S-adenosylmethionine and nicotinic acid originating from liver progenitor cells.
- The protection of UCK2 protein stability by GART maintains pyrimidine salvage synthesis for HCC growth under glucose limitation.
- Hepatocellular carcinoma: signaling pathways and therapeutic advances.
- GPC3-targeted CAR-T cells expressing GLUT1 or AGK exhibit enhanced antitumor activity against hepatocellular carcinoma.
- Upregulation of EFCAB7 after radiofrequency ablation promoting hepatocellular carcinoma metastasis and survival by regulating PARK7.
- Targeting the immune privilege of tumor-initiating cells to enhance cancer immunotherapy.
- CPT1A loss disrupts BCAA metabolism to confer therapeutic vulnerability in TP53-mutated liver cancer.
- SSRI antidepressant citalopram reverses the Warburg effect to inhibit hepatocellular carcinoma by directly targeting GLUT1.
- Lactate score classification of hepatocellular carcinoma helps identify patients with tumors that respond to immune checkpoint blockade therapy.
- TENT5A mediates the cancer-inhibiting effects of EGR1 by suppressing the protein stability of RPL35 in hepatocellular carcinoma.
- Macroscopic inhibition of DNA damage repair pathways by targeting AP-2α with LEI110 eradicates hepatocellular carcinoma.
- DNA methylation regulator-based molecular subtyping and tumor microenvironment characterization in hepatocellular carcinoma.
- UBXN9 inhibits the RNA exosome function to promote T cell control of liver tumorigenesis.
- Histone methyltransferase KMT5C drives liver cancer progression and directs therapeutic response to PARP inhibitors.
- NR4A3 inhibits the tumor progression of hepatocellular carcinoma by inducing cell cycle G0/G1 phase arrest and upregulation of CDKN2AIP expression.
- Interleukin-25 as a Potential Biomarker in Lung Metastasis of Hepatocellular Carcinoma with HBV History in Chinese Patients: A Single Center, Case-control Study.
- Protein O-fucosyltransferase 1 promotes PD-L1 stability to drive immune evasion and directs liver cancer to immunotherapy.
- PSMD9 promotes the malignant progression of hepatocellular carcinoma by interacting with c-Cbl to activate EGFR signaling and recycling.
- Incorporating AFP-L3 and DCP in selecting patients with hepatocellular carcinoma for liver transplantation: What are the optimal criteria?
- UBXN1 promotes liver tumorigenesis by regulating mitochondrial homeostasis.
- Transposable elements-mediated recruitment of KDM1A epigenetically silences HNF4A expression to promote hepatocellular carcinoma.
- Zbtb7b defines a compensatory mechanism in MASLD-related HCC progression by suppressing H19-mediated hepatic lipid deposition.
- Identification and validation of a prognostic model based on four genes related to satellite nodules in hepatocellular carcinoma.
- Efficacy and safety of lenvatinib plus gefitinib in lenvatinib-resistant hepatocellular carcinomas: a prospective, single-arm exploratory trial.
- Akkermansia muciniphila might improve anti-PD-1 therapy against HCC by changing host bile acid metabolism.
- GPX4 transcriptionally promotes liver cancer metastasis via GRHL3/PTEN/PI3K/AKT axis.
- A DNA/DMXAA/Metal-Organic Framework Activator of Innate Immunity for Boosting Anticancer Immunity.
- Landscape of immunocytes infiltration and prognostic immune-related genes in hepatocellular carcinoma.
- ScRNA-seq revealed targeting regulator of G protein signaling 1 to mediate regulatory T cells in Hepatocellular carcinoma.
- Combined local therapy and CAR-GPC3 T-cell therapy in advanced hepatocellular carcinoma: a proof-of-concept treatment strategy.
- Elevated nuclear PIGL disrupts the cMyc/BRD4 axis and improves PD-1 blockade therapy by dampening tumor immune evasion.
- Effect of infiltrating immune cells in tumor microenvironment on metastasis of hepatocellular carcinoma.
- The negative effect of G1958A polymorphism on MTHFD1 protein stability and HCC growth.
- KDM6A promotes hepatocellular carcinoma progression and dictates lenvatinib efficacy by upregulating FGFR4 expression.
- PET imaging of tumor vascular normalization in hepatocellular carcinoma.
- Relationship between SUVmax on 18F-FDG PET and PD-L1 expression in hepatocellular carcinoma.
- Copper and cuproptosis-related genes in hepatocellular carcinoma: therapeutic biomarkers targeting tumor immune microenvironment and immune checkpoints.
- Fibrinogen-like protein 1 promotes liver-resident memory T-cell exhaustion in hepatocellular carcinoma.
- Nucleolar HEAT Repeat Containing 1 Up-regulated by the Mechanistic Target of Rapamycin Complex 1 Signaling Promotes Hepatocellular Carcinoma Growth by Dominating Ribosome Biogenesis and Proteome Homeostasis.
- Gut microbial metabolite butyrate improves anticancer therapy by regulating intracellular calcium homeostasis.
- Overview and prospect of NAFLD: Significant roles of nutrients and dietary patterns in its progression or prevention.
- Syntaxin-6 promotes the progression of hepatocellular carcinoma and alters its sensitivity to chemotherapies by activating the USF2/LC3B axis.
- Drug Repurposing Flubendazole to Suppress Tumorigenicity via PCSK9-dependent Inhibition and Potentiate Lenvatinib Therapy for Hepatocellular Carcinoma.
- A negative feedback loop between KLF9 and the EMT program dictates metastasis of hepatocellular carcinoma.
- RIT1 regulates mitosis and promotes proliferation by interacting with SMC3 and PDS5 in hepatocellular carcinoma.
- hnRNPA2B1 promotes the occurrence and progression of hepatocellular carcinoma by downregulating PCK1 mRNA via a m6A RNA methylation manner.
- CCBE1 promotes mitochondrial fusion by inhibiting the TGFβ-DRP1 axis to prevent the progression of hepatocellular carcinoma.
- AKR1C3 suppresses ferroptosis in hepatocellular carcinoma through regulation of YAP/SLC7A11 signaling pathway.
- Evolving therapeutic landscape of advanced hepatocellular carcinoma.
- STAT3 palmitoylation initiates a positive feedback loop that promotes the malignancy of hepatocellular carcinoma cells in mice.
- Combating inconsistent evaluation of intra-tumor immune status by a novel transcriptomic signature in hepatocellular carcinoma.
- Aggregation-Induced Emission (AIE) and Magnetic Resonance Imaging Characteristics for Targeted and Image-Guided siRNA Therapy of Hepatocellular Carcinoma.
- Combination of ferroptosis and pyroptosis to construct a prognostic classifier and predict immune landscape, chemotherapeutic efficacy and immunosuppressive molecules in hepatocellular carcinoma.
- Inhibition of Autophagy Promotes the Elimination of Liver Cancer Stem Cells by CD133 Aptamer-Targeted Delivery of Doxorubicin.
- Sperm associated antigen 4 promotes SREBP1-mediated de novo lipogenesis via interaction with lamin A/C and contributes to tumor progression in hepatocellular carcinoma.
- ETV4 potentiates nuclear YAP retention and activities to enhance the progression of hepatocellular carcinoma.
- GPC3-targeted immunoPET imaging of hepatocellular carcinomas.
- Crucial role of T cells in NAFLD-related disease: A review and prospect.
- Tissue-resident memory T cells in chronic liver diseases: Phenotype, development and function.
- Multi-region sequencing with spatial information enables accurate heterogeneity estimation and risk stratification in liver cancer.
- A pre‑clinical model combining cryopreservation technique with precision‑cut slice culture method to assess the in vitro drug response of hepatocellular carcinoma.
- Tuftelin 1 Facilitates Hepatocellular Carcinoma Progression through Regulation of Lipogenesis and Focal Adhesion Maturation.
- STAT5A modulates CDYL2/SLC7A6 pathway to inhibit the proliferation and invasion of hepatocellular carcinoma by targeting to mTORC1.
- CaCO3 -Encapuslated Microspheres for Enhanced Transhepatic Arterial Embolization Treatment of Hepatocellular Carcinoma.
- Exploring subclass-specific therapeutic agents for hepatocellular carcinoma by informatics-guided drug screen.
- Prognosis and personalized treatment prediction in TP53-mutant hepatocellular carcinoma: an in silico strategy towards precision oncology.
- Deubiquitination of the repressor E2F6 by USP22 facilitates AKT activation and tumor growth in hepatocellular carcinoma.
- XRCC2 repairs mitochondrial DNA damage and fuels malignant behavior in hepatocellular carcinoma.
- NEIL3 Prevents Senescence in Hepatocellular Carcinoma by Repairing Oxidative Lesions at Telomeres during Mitosis.
- A Positive Feedback Loop of AKR1C3-Mediated Activation of NF-κB and STAT3 Facilitates Proliferation and Metastasis in Hepatocellular Carcinoma.
- MiR-103a promotes tumour growth and influences glucose metabolism in hepatocellular carcinoma.
- Inhibition of AMPK activity by TRIM11 facilitates cell survival of hepatocellular carcinoma under metabolic stress.
- A cascade-network framework for integrated registration of liver DCE-MR images.
- Global DNA 5hmC and CK195hmC+ Contents: A Promising Biomarker for Predicting Prognosis in Small Hepatocellular Carcinoma.
- Impact of statin use on the risk and prognosis of hepatocellular carcinoma: a meta-analysis.
- Novel SREBP1 inhibitor cinobufotalin suppresses proliferation of hepatocellular carcinoma by targeting lipogenesis.
- Neoadjuvant Programmed Cell Death 1 (PD-1) Inhibitor Treatment in Patients With Hepatocellular Carcinoma Before Liver Transplant: A Cohort Study and Literature Review.
- Targeting CDC7 potentiates ATR-CHK1 signaling inhibition through induction of DNA replication stress in liver cancer.
- Microwave ablation for peribiliary hepatocellular carcinoma: propensity score analyses of long-term outcomes.
- The role of tumor-associated macrophages in primary hepatocellular carcinoma and its related targeting therapy.
- Ultrasound-guided percutaneous microwave ablation for hepatocellular carcinoma originating in the caudate lobe: A pilot clinical study.
- C-C chemokine hepatocellular carcinoma motif ligand 5-deficiency promotes hepatocellular carcinoma progression by affecting B cell recruitment.
- ACTN1 supports tumor growth by inhibiting Hippo signaling in hepatocellular carcinoma.
- Metformin suppresses interleukin-22 induced hepatocellular carcinoma by upregulating Hippo signaling pathway.
- Identification of the Different Gene Expression Characteristics from Liver Cirrhosis to Hepatocellular Carcinoma Using Single-Cell Sequencing Analyses.
- An antibody-free liver cancer screening approach based on nanoplasmonics biosensing chips via spectrum-based deep learning.
- EGFR activation limits the response of liver cancer to lenvatinib.
- Exploring liver cancer biology through functional genetic screens.
- Nuclear scaffold protein p54nrb/NONO facilitates the hypoxia-enhanced progression of hepatocellular carcinoma.
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status30
- FGF19 Overexpression Combination Unified Study in HCC-19
- HAIC + Atezolizumab Plus Bevacizumab in Unresectable HCC
- DEB-TACE Prior to Liver Transplantation in the Treatment of HCC
- Prospective Real-World Study of HAIC With Raltitrexed or 5-Fluorouracil for the Treatment of Hepatocellular Carcinoma
- GPC3-directed CAR-T in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma
- Safety and Efficacy Study of Lenvatinib Combined With VIC-1911 for the Treatment of Advanced HCC
- Lenvatinib Plus VIC-1911 in Lenvatinib-unresponsive or Lenvatinib-resistant HCC
- IMRT Plus PD-1 Blockade and Lenvatinib for HCC With PVTT (Vp3) Before Liver Transplantation
- Effects of Anesthetic Methods on Hepatic Cancer Cell Function in Vitro
- Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 )
- Pembrolizumab and LENvatinib in Participants With Hepatocellular Carcinoma (HCC) Before Liver Transplant
- Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular Carcinoma
- Heterogeneity and Evolution of hepatoceLlular Carcinoma in Post-transplant HCC Recurrence
- Effects of Anesthetic Methods on Hepatic Cancer Cell Malignancy
- CAR-GPC3 T Cells in Patients With Refractory Hepatocellular Carcinoma
- Clinical and Basic Study for Pediatric Liver Transplantation
- Anti-GPC3 CAR T for Treating Patients With Advanced HCC
- ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
- A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)
- A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
- A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
- IMC001 for Clinical Research on Advanced Digestive System Malignancies
- A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
- To Evaluate the Safety and Efficacy of Microwave Ablation Therapy in Patients With Primary Liver Cancer
- A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
- Chimeric Antigen Receptor T Cells Targeting Glypican-3
- NeuWave Microwave Ablation HCC China Study
- Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
- Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma Following Local Ablation
- A Study of GPC3 Redirected Autologous T Cells for Advanced HCC
Cancer
Stomach cancer
胃癌Led 65 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.7%.
18 hospitals in Shanghai for stomach cancer218 hospitals in China for stomach cancer
Open trials with this hospital 12
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingImmunoPET Imaging of Pancreatic Cancer
- Phase
- N/A
- Started
- 2024-11
- Registry
- NCT06602037
Age 18 years to 70 years (registered criteria)
Led by Renji HospitalShanghai
- RecruitingTarget-specific immunoPET Imaging of Digestive System Carcinoma
- Phase
- N/A
- Started
- 2024-12
- Registry
- NCT06715839
Age 18 years to 75 years (registered criteria)
Led by Renji HospitalShanghai
- RecruitingThe Efficacy and Safety of the COMBO Endoscopy Oropharyngeal Airway in Gastrointestinal Endoscopy Procedure
- Phase
- N/A
- Started
- 2023-12
- Registry
- NCT06081647
Age 18 years to 60 years (registered criteria)
Led by Renji Hospital; 7 listed hospitals as study sitesHangzhou, Jinan, Nanchang, Nanjing, Shanghai
- RecruitingAtrophic Gastritis Predicts the Risk of Gastric Cancer
- Phase
- Not given
- Started
- 2023-12
- Registry
- NCT06203327
Age 18 years to 70 years (registered criteria)
Led by Renji HospitalShanghai
- Not yet recruitingSurufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation
- Phase
- Phase 2
- Started
- 2024-08
- Registry
- NCT06531291
Age 18 years to 75 years (registered criteria)
Led by Renji HospitalShanghai
- RecruitingOral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer
- Phase
- N/A
- Started
- 2026-06
- Registry
- NCT07552402
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Nanning, Shanghai, Shijiazhuang, Suzhou, Wuhan, Yinchuan
- RecruitingA Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
- Phase
- Phase 3
- Started
- 2025-05
- Registry
- NCT06901531
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Shanghai, Shijiazhuang, Tianjin, Wuhan, Zhengzhou
- RecruitingBovine Reinforcement in Stomach, Colorectal and Lung Operation
- Phase
- Phase 3
- Started
- 2025-05
- Registry
- NCT06968221
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2025-07
- Registry
- NCT07066657
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Changsha, Chongqing, Hangzhou, Harbin, Shanghai, Wuhan, Zhengzhou
- RecruitingAdjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer
- Phase
- Phase 3
- Started
- 2025-12
- Registry
- NCT07366528
Age 18 years to 80 years (registered criteria)
Led by Ruijin Hospital; 3 listed hospitals as study sitesShanghai
- RecruitingA Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
- Phase
- Phase 3
- Started
- 2024-11
- Registry
- NCT06532006
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Lanzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Xiamen, Xuzhou, Yinchuan, Zhengzhou
- Not yet recruitingAI-Assisted Novel rbcDNA Detection for Early Gastric Cancer Diagnosis
- Phase
- Not given
- Started
- 2026-09
- Registry
- NCT07782294
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang University; 2 listed hospitals as study sitesAnyang, Hangzhou, Shanghai
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led65
- Bi-phase CT radiomics nomogram for the preoperative prediction of pylorus lymph node metastasis in non-pyloric gastric cancer patients.
- Long-term outcomes and quality of life of laparoscopic-assisted pylorus-preserving gastrectomy compared to laparoscopic-assisted distal gastrectomy with billroth I anastomosis for early gastric cancer(pT1N0M0): A Randomized Controlled Trial
- Burden, trends, driving factors, and predictions of gastric cancer: a cross-national comparative analysis of China, Japan, and South Korea.
- Clinical study of adebrelimab in combination with apatinib and irinotecan for PD-1 inhibitor-ineffective advanced-stage gastric cancer: study protocol for a single-arm, single-centre, exploratory trial.
- Metabolic fingerprinting enables rapid, label-free histopathology in gastric cancer diagnosis and prognostic prediction.
- Nuclear translocation of CDK5RAP3 regulated by NXF3 promotes the progression of gastric cancer.
- Surufatinib plus paclitaxel as second-line therapy for advanced gastric cancer: a single-arm, phase 2 clinical trial.
- High extracellular matrix stiffness upregulates TNNT1 to awaken dormant tumor cells in liver metastatic niches of gastric cancer.
- CST1 promoted gastric cancer development by activating the AKT pathway.
- Automated interpretation of PD-L1 CPS based on multi-AI models integration strategy in gastric cancer.
- Staging of operative link on gastritis assessment and operative link on gastric intestinal metaplasia systems for risk assessment of early gastric cancer: a case-control study.
- Clinicopathological Characteristics of Gastric Cancer in China: A 16-Year Single-Center Retrospective Clinical Study.
- A machine learning-enhanced gastric cancer diagnostic method based on shell-isolated nanoparticle-enhanced Raman spectroscopy.
- DEPP1: A prognostic biomarker linked to stroma‑rich and immunosuppressive microenvironment, promoting oxaliplatin resistance in gastric cancer.
- Renji endoscopic submucosal dissection video data set for early gastric cancer.
- A Retrospective Study of Laparoscopic Distal Gastrectomy Guided by Carbon Nanoparticle Suspension Injection Lymphography for Gastric Cancer.
- Comprehensive exome profiling identifies ARHGEF12 mutation as a driver in gastric cancer with ovarian metastasis.
- Effectiveness of circulating tumor cells and circulating tumor DNA in peritoneal lavage fluid for predicting metachronous peritoneal metastasis of gastric cancer.
- Total laparoscopy-assisted total gastrectomy with Da Vinci robotic system conducted by robotic enhanced neurocomputing joint intelligence gastrointestinal surgery hub (RENJI-GISH): a preliminary clinical study and case report.
- Comprehensive analysis of T-cell regulatory factors and tumor immune microenvironment in stomach adenocarcinoma.
- Effectiveness of peritoneal lavage fluid circulating tumour cells and circulating tumour DNA in the prediction of metachronous peritoneal metastasis of gastric cancer (pT4NxM0/pT1-3N+M0) after radical resection: protocol of a prospective si
- Leveraging synthetic lethality to uncover potential therapeutic target in gastric cancer.
- Circadian system disorder induced by aberrantly activated EFNB2-EPHB2 axis leads to facilitated liver metastasis in gastric cancer.
- Single-cell RNA transcriptomic analyses of tumor microenvironment of ovarian metastasis in gastric cancer.
- Serum Circulating mRNA Panel for the Early Detection of Gastric Cancer: A Potential Biomarker Test.
- ImmunoPET imaging of Trop2 expression in solid tumors with nanobody tracers.
- [68Ga]Ga-FAPI-04 PET/MR imaging strategy in management of Krukenberg tumors (KTs) from gastric signet-ring-cell carcinoma: to overcome limitation of [68Ga]Ga-FAPI-04 PET imaging in KTs.
- Chromosomal copy number amplification-driven Linc01711 contributes to gastric cancer progression through histone modification-mediated reprogramming of cholesterol metabolism.
- Effectiveness and safety of Moluodan in the treatment of precancerous lesions of gastric cancer: A randomized clinical trial.
- Association of PD-1 + Treg/PD-1 + CD8 ratio and tertiary lymphoid structures with prognosis and response in advanced gastric cancer patients receiving preoperative treatment.
- Targeting cellular senescence as a therapeutic vulnerability in gastric cancer.
- DNA methyltransferase 3a-induced hypermethylation of the fructose-1,6-bisphosphatase-2 promoter contributes to gastric carcinogenesis.
- CCL19/CCR7 drives regulatory T cell migration and indicates poor prognosis in gastric cancer.
- SIGLEC10+ macrophages drive gastric cancer progression by suppressing CD8+ T cell function.
- Setd2 deficiency promotes gastric tumorigenesis through inhibiting the SIRT1/FOXO pathway.
- MAOA suppresses the growth of gastric cancer by interacting with NDRG1 and regulating the Warburg effect through the PI3K/AKT/mTOR pathway.
- The SLITRK4-CNPY3 axis promotes liver metastasis of gastric cancer by enhancing the endocytosis and recycling of TrkB in tumour cells.
- Tumor-associated macrophage-derived GDNF promotes gastric cancer liver metastasis via a GFRA1-modulated autophagy flux.
- Gastric metastasis from renal cell carcinoma 13 years after nephrectomy.
- First Total-Body Kinetic Modeling and Parametric Imaging of Dynamic 68Ga-FAPI-04 PET in Pancreatic and Gastric Cancer.
- Clinical outcomes and potential therapies prediction of subgroups based on a ferroptosis-related long non-coding RNA signature for gastric cancer.
- Delivery of LINC00589 via mesoporous silica nanoparticles inhibits peritoneal metastasis in gastric cancer.
- Fecal Signatures of Streptococcus anginosus and Streptococcus constellatus for Noninvasive Screening and Early Warning of Gastric Cancer.
- Endoscopic, clinicopathological, and growth characteristics of minute gastric cancer.
- Synchronous in situ follicular neoplasia with MALT lymphoma and intramucosal adenocarcinoma in the stomach: A case report.
- Trends of stomach cancer survival: A systematic review of survival rates from population-based cancer registration.
- Neutrophil extracellular traps promote metastasis in gastric cancer patients with postoperative abdominal infectious complications.
- Precise Targeting Therapy of Orthotopic Gastric Carcinoma by siRNA and Chemotherapeutic Drug Codelivered in pH-Sensitive Nano Platform.
- Plasmonic Alloys Reveal a Distinct Metabolic Phenotype of Early Gastric Cancer.
- Tea Drinking and Risk of Cancer Incidence: A Meta-Analysis of Prospective Cohort Studies and Evidence Evaluation.
- Neo-adjuvant radiation therapy provides a survival advantage in T3-T4 nodal positive gastric and gastroesophageal junction adenocarcinoma: a SEER database analysis.
- Age is the only predictor for upper gastrointestinal malignancy in Chinese patients with uncomplicated dyspepsia: a prospective investigation of endoscopic findings.
- Stomach-specific c-Myc overexpression drives gastric adenoma in mice through AKT/mammalian target of rapamycin signaling.
- CHPF promotes gastric cancer tumorigenesis through the activation of E2F1.
- ZEB1-induced LINC01559 expedites cell proliferation, migration and EMT process in gastric cancer through recruiting IGF2BP2 to stabilize ZEB1 expression.
- mTOR signaling regulates gastric epithelial progenitor homeostasis and gastric tumorigenesis via MEK1-ERKs and BMP-Smad1 pathways.
- The Mechanism of Asparagine Endopeptidase in the Progression of Malignant Tumors: A Review.
- Specific epigenetic age acceleration patterns among four molecular subtypes of gastric cancer and their prognostic value.
- Patterns of Lymph Node Metastasis in Patients With T1/T2 Gastroduodenal Neuroendocrine Neoplasms: Implications for Endoscopic Treatment.
- Preservation of hepatic branch of the vagus nerve reduces the risk of gallstone formation after gastrectomy.
- Diagnostic endoscopic submucosal dissection in the diagnosis of biopsy-missed gastric mucosa-associated lymphoid tissue lymphoma.
- Norepinephrine Enhances Aerobic Glycolysis and May Act as a Predictive Factor for Immunotherapy in Gastric Cancer.
- Disruption of KDM4C-ALDH1A3 feed-forward loop inhibits stemness, tumorigenesis and chemoresistance of gastric cancer stem cells.
- Poorly differentiated is more significant than signet ring cell component for lymph node metastasis in mixed-type early gastric cancer: a retrospective study from a large-volume hospital.
- Sema3C promotes hepatic metastasis and predicts poor prognosis in gastric adenocarcinoma.
Chinese-language papers (not in the count)8
- [Long-term prognosis of surgical treatment for peri-gastric cardial gastrointestinal stromal tumors].
- [Thinking and strategy selection on the quality control of early gastric cancer].
- [Statistical analysis of disability-adjusted life years for stomach and colorectal cancers in Changning District of Shanghai].
- [Multiple primary malignancies combined with SWI/SNF complex-deficient gastric cancer: a case report and literature review].
- [Influence of postoperative complications on prognosis of gastric cancer-The manifestation of gastric surgeon's skill, responsibility and empathy].
- [Current status and progression of minimally invasive surgery after neoadjuvant therapy for adenocarcinoma of esophagogastric junction].
- [Clinical significance of the deep learning algorithm based on contrast-enhanced CT in the differential diagnosis of gastric gastrointestinal stromal tumors with a diameter ≤ 5 cm].
- [Choice of function-preserving gastrectomy].
All its trials on ClinicalTrials.gov, any status43
- Target-specific immunoPET Imaging of Digestive System Carcinoma
- Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation
- ImmunoPET Imaging of Pancreatic Cancer
- The Efficacy and Safety of the COMBO Endoscopy Oropharyngeal Airway in Gastrointestinal Endoscopy Procedure
- A Study to Evaluate Serplulimab in Combination With Docetaxel +S-1 VS. Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage IIIc Gastric Cancer
- Efficacy and Safety of Fruquintinib With Sintilimab as First-line Therapy in Gastric Cancer
- Dose Exploration of Ciprofol for Sedation in Gastrointestinal Endoscopic Diagnosis and Treatment of Obese Patients.
- Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients
- HFNO Combined With NPA Reduces Hypoxia During Sedated Gastrointestinal Endoscopy In Obese Patients
- HFNO Reduces Hypoxia During Sedated Gastroscopy or Colonoscopy in High Risk Patients
- Anxiety Before Non-cardiac Surgery in Adults
- Nasal Mask Kit in Gastrointestinal Endoscopy
- High-flow Nasal Cannula Oxygenation Decrease Hypoxia in Sedated Gastrointestinal Endoscopes in Obesity
- Efficacy and Safety of Remimazolam Tosylate for Sedation in Gastroscopy
- Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients
- Safety and Feasibility of Reversible Induction Strategy
- Capnographic Monitoring in Gastrointestinal Endoscopy for Elderly Patients
- A Study to Evaluate Camrelizumab in Combination With Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage III Gastric Cancer
- Safety of Laparoscopic Resection for Gastrointestinal Stromal Tumor on Unfavorable Anatomic Site of Stomach
- High-flow Nasal Cannula Oxygenation Decrease Hypoxia in Gastroscopy Sedated by Propofol
- Laparoscopy-assisted Pylorus-vagus Nerve Preserving Gastrectomy in the Treatment of Early Gastric Cancer
- WEI NASAL JET for The Sedation of Outpatient Upper Gastrointestinal Endoscopy
- Adverse Events During Upper Gastrointestinal Endoscopy
- Atrophic Gastritis Predicts the Risk of Gastric Cancer
- Correlation of Endoscopic Findings and Symptoms in Patients Undergoing the First Upper Gastrointestinal Endoscopy
- Necessity Assessment of ME-NBI Targeted Biopsy Compared With EFB
- Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer
- AI-Assisted Novel rbcDNA Detection for Early Gastric Cancer Diagnosis
- A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
- A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
- Bovine Reinforcement in Stomach, Colorectal and Lung Operation
- Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer
- A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
- IMC001 for Clinical Research on Advanced Digestive System Malignancies
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension
- A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer Diagnosis
- Study of Faecal Bacteria Detection in Early Screening and Diagnosis of GC
- Laparoscopic D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancers
- Incidence of Pancreatic Fistula After Radical Gastrectomy
- Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)
- Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Gastric Cancer
- A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer
- Multicenter Study on Laparoscopic Distal Subtotal Gastrectomy for Advanced Gastric Cancer (CLASS-01)
Cancer
Hepatoblastoma
肝母细胞瘤Led 3 of the 154 English-language PubMed papers on hepatoblastoma with an author in mainland China, 2021–2025: 1.9%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
8 hospitals in Shanghai for hepatoblastoma88 hospitals in China for hepatoblastoma
No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led3
- IMPDH2 suppression impedes cell proliferation by instigating cell cycle arrest and stimulates apoptosis in pediatric hepatoblastoma.
- Pediatric Hepatoblastoma After Neoadjuvant Chemotherapy: Diagnostic Performance of MR in Staging POSTTEXT and Vascular Involvement.
- Single-cell transcriptomics uncovers cellular architecture and developmental trajectories in hepatoblastoma.
All its trials on ClinicalTrials.gov, any status2
Cancer
Retinoblastoma
视网膜母细胞瘤Led 1 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
11 hospitals in Shanghai for retinoblastoma196 hospitals in China for retinoblastoma
No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Cancer
Chordoma
脊索瘤Led 1 of the 105 English-language PubMed papers on chordoma with an author in mainland China, 2021–2025: 0.9%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
15 hospitals in Shanghai for chordoma88 hospitals in China for chordoma
No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Cancer
Osteosarcoma
骨肉瘤Led 3 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
60 hospitals in Shanghai for osteosarcoma742 hospitals in China for osteosarcoma
No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led3
- Long-Circulating and Targeted Liposomes Co-loading Cisplatin and Mifamurtide: Formulation and Delivery in Osteosarcoma Cells.
- Deciphering the role of lipid metabolism and acetylation in osteosarcoma: A comprehensive molecular analysis.
- Clinical significance of adjuvant therapy after radical surgery for primary osteosarcoma of the jaws.
Earlier papers (2016–2020)16
- Long noncoding RNA SNHG8 promotes the proliferation of osteosarcoma cells by downregulating miR-542-3p.
- Polydatin induces apoptosis and autophagy via STAT3 signaling in human osteosarcoma MG-63 cells.
- Organoid culture system for patient-derived lung metastatic osteosarcoma.
- MicroRNA-876-5p inhibits cell proliferation, migration and invasion by targeting c-Met in osteosarcoma.
- Long non-coding RNA HOXA-AS2 promotes migration and invasion by acting as a ceRNA of miR-520c-3p in osteosarcoma cells.
- SLIT2/ROBO1 axis contributes to the Warburg effect in osteosarcoma through activation of SRC/ERK/c-MYC/PFKFB2 pathway.
- miR-149-5p inhibits cell growth by regulating TWEAK/Fn14/PI3K/AKT pathway and predicts favorable survival in human osteosarcoma.
- MicroRNA-124 suppresses growth and aggressiveness of osteosarcoma and inhibits TGF-β-mediated AKT/GSK-3β/SNAIL-1 signaling.
- Activation of TNF-α/NF-κB axis enhances CRL4BDCAF11 E3 ligase activity and regulates cell cycle progression in human osteosarcoma cells.
- SPARCL1 suppresses osteosarcoma metastasis and recruits macrophages by activation of canonical WNT/β-catenin signaling through stabilization of the WNT-receptor complex.
- Generating lung-metastatic osteosarcoma targeting aptamers for in vivo and clinical tissue imaging.
- Paraoxonase 3 promotes cell proliferation and metastasis by PI3K/Akt in oral squamous cell carcinoma.
- Long non-coding RNA XIST regulates PDCD4 expression by interacting with miR-21-5p and inhibits osteosarcoma cell growth and metastasis.
- miR-92a promotes tumor growth of osteosarcoma by targeting PTEN/AKT signaling pathway.
- CRL4BDCAF11 E3 ligase targets p21 for degradation to control cell cycle progression in human osteosarcoma cells.
- MicroRNA-30a downregulation contributes to chemoresistance of osteosarcoma cells through activating Beclin-1-mediated autophagy.
Cancer
Gastrointestinal stromal tumour
胃肠道间质瘤Led 10 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 1.9%.
- Open trials led
- 0
- recruiting or about to
21 hospitals in Shanghai for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingEfficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
- Phase
- Phase 2/Phase 3
- Started
- 2026-05
- Registry
- NCT07379047
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Wuhan, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led10
- Development and validation of a machine-learning-based pathomics nomogram for predicting recurrence of localized primary gastrointestinal stromal tumors after complete surgical resection: A retrospective multicenter study.
- Aptamer-based drug delivery for targeted therapy of imatinib-resistant gastrointestinal stromal tumor.
- Identification of D842V mutation in gastrointestinal stromal tumors based on CT radiomics: a multi-center study.
- Drugs in the GIST Field (Therapeutic Targets and Clinical Trial Staging).
- Prediction of high Ki-67 proliferation index of gastrointestinal stromal tumors based on CT at non-contrast-enhanced and different contrast-enhanced phases.
- Clinical importance of tumor rupture in gastrointestinal stromal tumor.
- Adult Female Patient with Untreated Truncus Arteriosus Type I and Torsion of Small Bowel Gastrointestinal Stromal Tumor: A Rare Case Report.
- Personalized radiomics signature to screen for KIT-11 mutation genotypes among patients with gastrointestinal stromal tumors: a retrospective multicenter study.
- The nerve-tumour regulatory axis GDNF-GFRA1 promotes tumour dormancy, imatinib resistance and local recurrence of gastrointestinal stromal tumours by achieving autophagic flux.
- Low Distribution of TIM-3+ Cytotoxic Tumor-Infiltrating Lymphocytes Predicts Poor Outcomes in Gastrointestinal Stromal Tumors.
Chinese-language papers (not in the count)7
- [Long-term prognosis of surgical treatment for peri-gastric cardial gastrointestinal stromal tumors].
- [Prognosis and its influencing factors in patients with non-gastric gastrointestinal stromal tumors at low risk of recurrence: a retrospective multicenter study in China].
- [Rethinking several issues related to surgical treatment for advanced GIST in the era of targeted therapy].
- [Identification and inner relation between gastrointestinal stromal tumor and intra-abdominal desmoid tumor].
- [Clinicopathological features and prognosis of gastrointestinal stromal tumors with KIT/PDGFRA gene "homozygous mutation": a multicenter retrospective cohort study].
- [Clinical significance of the deep learning algorithm based on contrast-enhanced CT in the differential diagnosis of gastric gastrointestinal stromal tumors with a diameter ≤ 5 cm].
- [Act following etiquette and change with time: analysis and discussion on the difference between the current guidelines and clinical practice of gastrointestinal stromal tumor].
Earlier papers (2016–2020)15
- Exon 11 homozygous mutations and intron 10/exon 11 junction deletions in the KIT gene are associated with poor prognosis of patients with gastrointestinal stromal tumors.
- Clinicopathologic characteristics, diagnostic clues, and prognoses of patients with multiple sporadic gastrointestinal stromal tumors: a case series and review of the literature.
- Recurrent Extra-gastrointestinal Stromal Tumor of the Vagina: A Case Report and Review of the Literature.
- [Clinicopathological features and prognosis of gastrointestinal stromal tumor with PDGFRA-D842V mutation].
- [Updates and interpretations of the NCCN Clinical Practice Guidelines (2019 6th version) on gastrointestinal stromal tumor].
- [Pitfalls and dilemmas in the decision-making process of diagnosis and treatment on gastrointestinal stromal tumor].
- Aberrant accumulation of Dickkopf 4 promotes tumor progression via forming the immune suppressive microenvironment in gastrointestinal stromal tumor.
- [Application of imatinib plasma concentration monitoring in the whole process management of gastrointestinal stromal tumor patients].
- [Similarities and differences in diagnosis and treatment of gastrointestinal stromal tumors between China, Japan and Korea: from expert consensus to cooperation prospect].
- miR-182 controls cell growth in gastrointestinal stromal tumors by negatively regulating CYLD expression.
- miRNA-218-loaded carboxymethyl chitosan - Tocopherol nanoparticle to suppress the proliferation of gastrointestinal stromal tumor growth.
- [Targeted therapy combined with immunotherapy in gastrointestinal stromal tumor: a new era of hope and challenges].
- CCBE1 promotes GIST development through enhancing angiogenesis and mediating resistance to imatinib.
- [Lancet in the era of targeted drug therapy: the role of surgery in the management of advanced gastrointestinal stromal tumor].
- [New challenges in the diagnosis and treatment of gastrointestinal stromal tumor: thinking and practice from evidence-based medicine to precision medicine].
All its trials on ClinicalTrials.gov, any status9
- Ripretinib Used for Resectable Metastatic GIST After Failure of Imatinib Therapy
- Safety of Laparoscopic Resection for Gastrointestinal Stromal Tumor on Unfavorable Anatomic Site of Stomach
- Serum Dickkopf-4 as a Biomarker for the Diagnosis and Treatment of Gastrointestinal Stromal Tumor
- Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
- Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
- A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)
- A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib
- A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor
- (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
Cancer
Neuroblastoma
神经母细胞瘤Led 2 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.2%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
34 hospitals in Shanghai for neuroblastoma352 hospitals in China for neuroblastoma
No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led2
Earlier papers (2016–2020)2
All its trials on ClinicalTrials.gov, any status1
Blood disorders
Multiple myeloma
多发性骨髓瘤Led 24 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 1.4%.
16 hospitals in Shanghai for multiple myeloma178 hospitals in China for multiple myeloma
Open trials with this hospital 6
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- Not yet recruitingAllogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cells (ACT-001) in Patients With Relapsed or Refractorymultiple Myeloma
- Phase
- N/A
- Started
- 2024-10
- Registry
- NCT06594211
Age 18 years to 75 years (registered criteria)
Led by Renji HospitalShanghai
- Enrolling by invitationLong-term Follow-up Study in Subjects With Multiple Myeloma Previously Treated With GC012F Injection
- Phase
- Not given
- Started
- 2026-11
- Registry
- NCT07833046
Age not stated (registered criteria)
Led by Renji HospitalShanghai
- RecruitingA Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma
- Phase
- Early phase 1
- Started
- 2026-04
- Registry
- NCT07493135
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingCevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- Phase
- Phase 3
- Started
- 2026-06
- Registry
- NCT07555938
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesGuangzhou, Hangzhou, Jinan, Kunming, Nanjing, Qingdao, Shanghai, Suzhou, Tianjin, Wenzhou, Wuhan
- RecruitingA Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2026-09
- Registry
- NCT07760454
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai, Suzhou
- RecruitingA Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Phase
- Phase 3
- Started
- 2022-10
- Registry
- NCT05552222
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led24
- Lipin1-dependent transcriptional inactivation of SREBPs contributes to selinexor sensitivity in multiple myeloma.
- Enhancer Extrachromosomal Circular DNA ANKRD28 Elicits Drug Resistance via POU2F2-Mediated Transcriptional Network in Multiple Myeloma.
- First-line anti-BCMA CAR-T cell therapy in a fragile patient with biclonal gammopathy and giant plasma cell tumor multiple myeloma with multiple comorbidities: a case report.
- Dual roles of IRE1α inhibition in reversing mitochondrial ROS-induced CD8+ T-cell senescence and exerting direct antitumor effects in multiple myeloma.
- Targeting deubiquitinase USP7-mediated stabilization of XPO1 contributes to the anti-myeloma effects of selinexor.
- Research progress of the chemokine/chemokine receptor axes in the oncobiology of multiple myeloma (MM).
- The added diagnostic value of 18 F-FDG PET/CT radiomic analysis in multiple myeloma patients with negative visual analysis.
- From Multiple Myeloma to Acute Myeloid Leukemia: A Case Report of a 61-year-old Woman after 8 Years of Chemotherapy and Immunotherapy.
- Integrating plasma proteomes with genome-wide association data for causal protein identification in multiple myeloma.
- Single-cell RNA sequencing reveals XBP1-SLC38A2 axis as a metabolic regulator in cytotoxic T lymphocytes in multiple myeloma.
- Distinct mechanisms of dysfunctional antigen-presenting DCs and monocytes by single-cell sequencing in multiple myeloma.
- Metabolic kinetic modeling of [11C]methionine based on total-body PET in multiple myeloma.
- Unravelling the imbalanced Th17-like cell differentiation by single-cell RNA sequencing in multiple myeloma.
- C-reactive protein impairs immune response of CD8+ T cells via FcγRIIb-p38MAPK-ROS axis in multiple myeloma.
- Recombinant human p53 adenovirus injection combined with Bortezomib inhibits proliferation and promotes apoptosis in multiple myeloma.
- Pharmacodynamic, pharmacokinetic, and phase 1a study of bisthianostat, a novel histone deacetylase inhibitor, for the treatment of relapsed or refractory multiple myeloma.
- Increased Expression of SETDB1 Predicts Poor Prognosis in Multiple Myeloma.
- Single-cell transcriptome profiling reveals the key role of ZNF683 in natural killer cell exhaustion in multiple myeloma.
- Promising therapeutic approaches for relapsed/refractory multiple myeloma.
- Causal relationships between inflammatory factors and multiple myeloma: A bidirectional Mendelian randomization study.
- Annotating CD38 Expression in Multiple Myeloma with [18F]F-Nb1053.
- Annotating BCMA Expression in Multiple Myelomas.
- ImmunoPET imaging of multiple myeloma with [68Ga]Ga-NOTA-Nb1053.
- Immunotherapeutic strategies targeting B cell maturation antigen in multiple myeloma.
Chinese-language papers (not in the count)3
- [Interpretation of diagnosis of multiple myeloma in the guidelines for the diagnosis and management of multiple myeloma in China (2022 revision)].
- [Effect of autologous hematopoietic stem cell transplantation on minimal residual disease in patients with multiple myeloma].
- [Detection of minimal residual disease in patients with multiple myeloma:current status, challenges and prospective].
All its trials on ClinicalTrials.gov, any status16
- Long-term Follow-up Study in Subjects With Multiple Myeloma Previously Treated With GC012F Injection
- Allogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cells (ACT-001) in Patients With Relapsed or Refractorymultiple Myeloma
- Id and Rd Maintenance Regimens After Induction of Remission in Multiple Myeloma.
- PVd Versus Vd in NDMM Patients With RI
- A Multicenter Cross-sectional Study on Mental Health of Patients With Multiple Myeloma
- Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma
- A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma
- A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma
- A Study of Daratumumab
- A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
- Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)
- Safety, Pharmacokinetics and Efficacy Study of Bisthianostat in Refractory or Recurrent Multiple Myeloma Patients
- A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
- A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)
Blood disorders
Haemophagocytic lymphohistiocytosis
噬血细胞性淋巴组织细胞增生症Led 3 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 0.8%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
5 hospitals in Shanghai for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
- Phase
- Phase 3
- Started
- 2025-11
- Registry
- NCT07208058
Age 16 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Nanchang, Shanghai, Shenyang, Shijiazhuang, Wuhan, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led3
- Hemophagocytic lymphohistiocytosis after solid organ transplantation: A challenge for clinicians.
- Short-term, low-dose etoposide in refractory adult-onset Still's disease-associated macrophage activation syndrome.
- Gastric ulcer as the main complication in hemophagocytic lymphohistiocytosis: A case report.
All its trials on ClinicalTrials.gov, any status2
- A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
- A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic Characteristics, and Immunogenicity of Plonmarlimab in Subjects With Rheumatic and Immunological Disease-associated Haemophagocytic Lymphohistiocytosis (HLH) (Also Known as Macrophage Activation Syndrome (MAS))
Blood disorders
Atypical haemolytic uraemic syndrome
非典型溶血性尿毒症综合征Led 1 of the 27 English-language PubMed papers on atypical haemolytic uraemic syndrome with an author in mainland China, 2021–2025: 3.7%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Shanghai for atypical haemolytic uraemic syndrome31 hospitals in China for atypical haemolytic uraemic syndrome
No open trial on atypical haemolytic uraemic syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
Other diseases
Neuromyelitis optica spectrum disorder
视神经脊髓炎谱系疾病Led 11 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 2.3%.
- Open trials as a site
- 0
- led by another institution
4 hospitals in Shanghai for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
- Phase
- Phase 1
- Started
- 2024-03
- Registry
- NCT06249438
Age 18 years to 70 years (registered criteria)
Led by Renji HospitalShanghai
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led11
- Influencing factors and clinical value of anti-aquaporin-4 antibody in cerebrospinal fluid: a study of 82 patients with neuromyelitis optica spectrum disorder.
- Telitacicept Inhibits the Maturation and Differentiation of B Lymphocytes in NMOSD.
- Multi-tracer PET and MR imaging visualize distinct metabolic and inflammatory profiles in the white matter of NMOSD and MOGAD.
- Efficacy of human umbilical cord mesenchymal stem cell in the treatment of neuromyelitis optica spectrum disorders: an animal study.
- Immunosuppressive therapy and COVID-19 infection in patients with NMOSD.
- Human NMO-IgG Induced Different Pathological and Immunological Changes in the CNS and Peripheral Tissues of Mice.
- Interactions Between Extracellular Vesicles and Autophagy in Neuroimmune Disorders.
- Telitacicept following plasma exchange in the treatment of subjects with recurrent neuromyelitis optica spectrum disorders: A single-center, single-arm, open-label study.
- Enlarged perivascular spaces, neuroinflammation and neurological dysfunction in NMOSD patients.
- Lymphocyte Subsets Are Associated with Disease Status in Neuromyelitis Optica Spectrum Disorders.
- Low Frequency Ultrasound With Injection of NMO-IgG and Complement Produces Lesions Different From Experimental Autoimmune Encephalomyelitis Mice.
All its trials on ClinicalTrials.gov, any status1
Other diseases
IgG4-related disease
IgG4相关性疾病Led 2 of the 246 English-language PubMed papers on IgG4-related disease with an author in mainland China, 2021–2025: 0.8%.
- Open trials led
- 0
- recruiting or about to
4 hospitals in Shanghai for IgG4-related disease46 hospitals in China for IgG4-related disease
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingStudy to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease
- Phase
- Phase 1/Phase 2
- Started
- 2026-01
- Registry
- NCT07061938
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Chengdu, Shanghai, Wuhan
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led2
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status3
More papers found outside PubMed (not counted)1
Other diseases
Myasthenia gravis
重症肌无力Led 3 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 0.6%.
- Open trials as a site
- 0
- led by another institution
7 hospitals in Shanghai for myasthenia gravis93 hospitals in China for myasthenia gravis
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
- Phase
- Phase 1
- Started
- 2024-03
- Registry
- NCT06249438
Age 18 years to 70 years (registered criteria)
Led by Renji HospitalShanghai
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led3
- Interactions Between Extracellular Vesicles and Autophagy in Neuroimmune Disorders.
- Drug-drug interaction between paxlovid and tacrolimus in a patient with myasthenia gravis and SARS-CoV-2 infection.
- A Stable Cell Line Expressing Clustered AChR: A Novel Cell-Based Assay for Anti-AChR Antibody Detection in Myasthenia Gravis.
All its trials on ClinicalTrials.gov, any status1
Other diseases
Biliary atresia
胆道闭锁Led 3 of the 214 English-language PubMed papers on biliary atresia with an author in mainland China, 2021–2025: 1.4%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Shanghai for biliary atresia28 hospitals in China for biliary atresia
No open trial on biliary atresia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led3
All its trials on ClinicalTrials.gov, any status2
More papers found outside PubMed (not counted)3
- Passenger Lymphocyte Syndrome with Hepatic Sinusoidal Obstruction Syndrome in an Infant Following Living Donor Liver Transplantation: An Association or Coincidence?
- Sequential Operation of Kasai Portoenterostomy and Liver Transplantation is Recommended in Biliary Atresia Children for Better Outcomes: A Propensity Score Matching Analysis
- Simultaneous pancreaticoduodenectomy and liver transplantation for biliary atresia complicated by choledochal cyst
Other diseases
Anti-NMDA receptor encephalitis
抗 NMDA 受体脑炎Led 2 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 0.8%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
9 hospitals in Shanghai for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis
No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led2
Other diseases
Takayasu arteritis
大动脉炎Led no English-language PubMed papers on Takayasu arteritis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
8 hospitals in Shanghai for Takayasu arteritis108 hospitals in China for Takayasu arteritis
No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
Other diseases
Idiopathic pulmonary fibrosis
特发性肺纤维化Led no English-language PubMed papers on idiopathic pulmonary fibrosis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
34 hospitals in Shanghai for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis
No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Chinese-language papers (not in the count)1
Earlier papers (2016–2020)1
Other diseases
Amyotrophic lateral sclerosis
肌萎缩侧索硬化症Led 3 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
17 hospitals in Shanghai for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis
No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led3
Other diseases
Fabry disease
法布雷病Led 1 of the 73 English-language PubMed papers on Fabry disease with an author in mainland China, 2021–2025: 1.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
6 hospitals in Shanghai for Fabry disease85 hospitals in China for Fabry disease
No open trial on Fabry disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Duchenne muscular dystrophy
杜氏肌营养不良Led no English-language PubMed papers on Duchenne muscular dystrophy in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
12 hospitals in Shanghai for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy
No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Behçet disease
白塞病Led 2 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.8%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
15 hospitals in Shanghai for Behçet disease149 hospitals in China for Behçet disease
No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led2
All its trials on ClinicalTrials.gov, any status1
Other diseases
IgA nephropathy
IgA 肾病Led 6 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.8%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
26 hospitals in Shanghai for IgA nephropathy346 hospitals in China for IgA nephropathy
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingPhase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN
- Phase
- Phase 3
- Started
- 2026-04
- Registry
- NCT07390123
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Changchun, Changsha, Huangshan City, Linyi, Shanghai, Wuhu, Xi'an, Zhanjiang
- RecruitingA Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
- Phase
- Phase 3
- Started
- 2025-07
- Registry
- NCT06963827
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBaotou, Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Nantong, Ningbo, Shanghai, Shenzhen, Wuxi, Xiamen, Zhuhai
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led6
- Urinary exosomal mRNAs as biomarkers for predicting the therapeutic effect of renin-angiotensin system inhibitors in IgA nephropathy patients.
- Molecular characterization of m6A RNA methylation regulators with features of immune dysregulation in IgA nephropathy.
- Downregulation of PPARα mediates FABP1 expression, contributing to IgA nephropathy by stimulating ferroptosis in human mesangial cells.
- A single-cell survey of the human glomerulonephritis.
- KM55 Monoclonal Antibody Staining in IgA-Dominant Infection-Related Glomerulonephritis.
- Leflunomide plus low-dose prednisone in patients with progressive IgA nephropathy: a multicenter, prospective, randomized, open-labeled, and controlled trial.
Earlier papers (2016–2020)3
- Serum miR-192 Is Related to Tubulointerstitial Lesion and Short-Term Disease Progression in IgA Nephropathy.
- Contrast-enhanced ultrasonography for assessment of tubular atrophy/interstitial fibrosis in immunoglobulin A nephropathy: a preliminary clinical study.
- Comparison of combined leflunomide and low-dose corticosteroid therapy with full-dose corticosteroid monotherapy for progressive IgA nephropathy.
All its trials on ClinicalTrials.gov, any status7
- Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN
- A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
- A Study of Telitacicept for IgA Nephropathy (TELIGAN)
- TESTING -ON Post-Trial ObservatioNal Cohort Study
- Atrasentan in Patients With IgA Nephropathy
- Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy
- Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)
Other diseases
Primary biliary cholangitis
原发性胆汁性胆管炎Led 17 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 5.7%.
17 hospitals in Shanghai for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis
Open trials with this hospital 3
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingBiochemical Response and Clinical Outcomes in Patients With PBC
- Phase
- Not given
- Started
- 2026-02
- Registry
- NCT07449793
Age 18 years to 85 years (registered criteria)
Led by Renji HospitalShanghai
- RecruitingA Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
- Phase
- Phase 3
- Started
- 2025-12
- Registry
- NCT07282353
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBaoji, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou, Harbin, Hefei, Linyi, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shiyan, Taizhou, Tianjin, Xi'an, Xiamen, Zhanjiang, Zhengzhou
- RecruitingSeladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
- Phase
- Phase 3
- Started
- 2023-09
- Registry
- NCT06051617
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Hefei, Shanghai, Urumqi, Wuhan, Xi'an, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led17
- The phenotypic and functional characteristics of intrahepatic CD69+CD103+ tissue-resident MAIT cells in primary biliary cholangitis.
- B cells drive CCR5+CD4+ tissue-resident memory T-cell cytotoxicity via IL-15Rα-IL-15 signaling in primary biliary cholangitis.
- Gut microbiome pattern impacts treatment response in primary biliary cholangitis.
- Osteoporosis and Primary Biliary Cholangitis: A Trans-ethnic Mendelian Randomization Analysis.
- Gut Microbiota-Derived Butyrate Induces Epigenetic and Metabolic Reprogramming in Myeloid-Derived Suppressor Cells to Alleviate Primary Biliary Cholangitis.
- Epidemiologic and genetic associations between primary biliary cholangitis and extrahepatic rheumatic diseases.
- Immunosuppression induces regression of fibrosis in primary biliary cholangitis with moderate-to-severe interface hepatitis.
- MGAT5/TMEM163 variant is associated with prognosis in ursodeoxycholic acid-treated patients with primary biliary cholangitis.
- Reply to: "ARID3A variant and the risk of primary biliary cholangitis in a Central European cohort".
- Intestinal microbiota in biliary diseases.
- Implications of gut microbiota in autoimmune liver diseases.
- A regulatory variant at 19p13.3 is associated with primary biliary cholangitis risk and ARID3A expression.
- Morphological, Functional, and Tissue Characterization of Silent Myocardial Involvement in Patients With Primary Biliary Cholangitis.
- Immunologic Responses and the Pathophysiology of Primary Biliary Cholangitis.
- NUDT1 promotes the accumulation and longevity of CD103+ TRM cells in primary biliary cholangitis.
- Prevalence and clinical characteristics of autoimmune liver disease in hospitalized patients with cirrhosis and acute decompensation in China.
- Alterations in microbiota and their metabolites are associated with beneficial effects of bile acid sequestrant on icteric primary biliary Cholangitis.
Chinese-language papers (not in the count)3
Earlier papers (2016–2020)17
- Epigenetics of Primary Biliary Cholangitis.
- Comprehensive Analysis of Serum and Fecal Bile Acid Profiles and Interaction with Gut Microbiota in Primary Biliary Cholangitis.
- Genome-wide Association Studies of Specific Antinuclear Autoantibody Subphenotypes in Primary Biliary Cholangitis.
- Cytotoxic KLRG1 expressing lymphocytes invade portal tracts in primary biliary cholangitis.
- Histologically proven AMA positive primary biliary cholangitis but normal serum alkaline phosphatase: Is alkaline phosphatase truly a surrogate marker?
- CTHRC1 expression in primary biliary cholangitis.
- [Clinicopathological analysis of anti-mitochondrial antibody negative primary biliary cholangitis-autoimmune hepatitis overlap syndrome].
- [Research advances of autoimmune liver diseases in 2018].
- Clinical analysis of liver transplantation in autoimmune liver diseases.
- The immunobiology of mucosal-associated invariant T cell (MAIT) function in primary biliary cholangitis: Regulation by cholic acid-induced Interleukin-7.
- Editorial: scoring systems in primary biliary cholangitis - time to make a move. Authors' reply.
- The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210.
- Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases.
- [Advances in the treatment of primary biliary cholangitis].
- [Research advances in autoimmune liver diseases in 2016].
- The Natural History and Prognosis of Primary Biliary Cirrhosis with Clinical Features of Autoimmune Hepatitis.
- A Common Variant in CLDN14 is Associated with Primary Biliary Cirrhosis and Bone Mineral Density.
All its trials on ClinicalTrials.gov, any status8
- Biochemical Response and Clinical Outcomes in Patients With PBC
- The Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe Itching
- Early Identification of Myocardial Impairment in PBC
- A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
- Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
- A Study of the Pharmacokinetics and Safety of CS0159 in Subjects With Hepatic Injury
- CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)
- Safety and Efficacy of Tauroursodeoxycholic Acid Versus Ursofalk in the Treatment of Adult Primary Biliary Cirrhosis
Other diseases
Primary sclerosing cholangitis
原发性硬化性胆管炎Led 5 of the 100 English-language PubMed papers on primary sclerosing cholangitis with an author in mainland China, 2021–2025: 5.0%.
- Open trials led
- 0
- recruiting or about to
13 hospitals in Shanghai for primary sclerosing cholangitis90 hospitals in China for primary sclerosing cholangitis
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
- Phase
- Phase 3
- Started
- 2026-05
- Registry
- NCT07387549
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changchun, Guangzhou, Jinan, Nanchang, Shanghai, Tianjin, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led5
- Itaconate inhibits CD103 + T RM cells and alleviates hepatobiliary injury in mouse models of primary sclerosing cholangitis.
- Intestinal microbiota in biliary diseases.
- P4HA2 induces hepatic ductular reaction and biliary fibrosis in chronic cholestatic liver diseases.
- Implications of gut microbiota in autoimmune liver diseases.
- Altered faecal microbiome and metabolome in IgG4-related sclerosing cholangitis and primary sclerosing cholangitis.
Chinese-language papers (not in the count)2
Earlier papers (2016–2020)10
- CTHRC1 expression in primary biliary cholangitis.
- [Research advances of autoimmune liver diseases in 2018].
- Clinical analysis of liver transplantation in autoimmune liver diseases.
- [Pathogenesis of immunoglobulin G4-related hepatobiliary disease].
- [Clinical observation of isolated immunoglobulin G4-related sclerosing cholangitis and immunoglobulin G4 sclerosing cholangitis combined autoimmune pancreatitis].
- [Research status and challenges in immunoglobulin G4-related hepatobiliary disease].
- Editorial: scoring systems in primary biliary cholangitis - time to make a move. Authors' reply.
- Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases.
- Comparative clinical characteristics and natural history of three variants of sclerosing cholangitis: IgG4-related SC, PSC/AIH and PSC alone.
- [Research advances in autoimmune liver diseases in 2016].
All its trials on ClinicalTrials.gov, any status4
- The Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe Itching
- Multicenter Observational Study of PSC and IgG4-SC in China
- A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
- CS0159 in Chinese Patients With PSC (Primary Sclerosing Cholangitis)
Other diseases
Hereditary angioedema
遗传性血管性水肿Led 2 of the 32 English-language PubMed papers on hereditary angioedema with an author in mainland China, 2021–2025: 6.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Shanghai for hereditary angioedema30 hospitals in China for hereditary angioedema
No open trial on hereditary angioedema lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led2
All its trials on ClinicalTrials.gov, any status1
Other linked evidence
Getting in touch
Name card to show staff or a driver
上海交通大学医学院附属仁济医院
Renji Hospital
上海
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.